10-1074 vs Lotivibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
10-1074
Developed by Gilead Sciences under a licence from The Rockefeller University
NCT03707977 · Phase 1/2 · completed
This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. All participants received 10-1074 together with a second antibody, VRC01LS, so the results describe the dual-antibody regimen, not 10-1074 alone. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.
Reported efficacy
Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant); Severity of Treatment-associated AEs (Number of Participants With Grade 3 or Higher Related AEs) (Measured until 30 days after study completion for each participant); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 400 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 40 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2): Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant): Group PK-A: ART + VRC01LS 4 Participants | Group PK-B: ART + 10-1074 1 Participants | Steps 1-3 Participants (ART + 10-1074 + VRC01LS) 19 Participants (not_applicable)
Result source: NCT03707977
Lotivibart
Developed by ViiV Healthcare
NCT04871113 · Phase 2 · completed
Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
Reported efficacy
Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Adverse Events (AEs) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase): Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) (not_applicable)
Result source: NCT04871113
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | 10-1074 | Lotivibart |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- 10-1074
- —Not reported
- Lotivibart
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- 10-1074
- —Not reported
- Lotivibart
- —Not reported
CD4 count, change (week 48)
- 10-1074
- —Not reported
- Lotivibart
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. 10-1074: 3 of 4 rows · Lotivibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | 10-1074 | Lotivibart |
|---|---|---|
| Dropout rate | 0%Group PK-B: ART + 10-1074 NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 show 3 more results—PK Step (ART + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 1 (ART + VRC01LS + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 2 (VRC01LS + 10-1074 Only) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 | —700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results—700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 12.5%3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination 0%60 mg/kg NCT05291520 · Phase 1 · monotherapy 0%20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Discontinued due to AEs | —Group PK-B: ART + 10-1074 NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 show 3 more results—PK Step (ART + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 1 (ART + VRC01LS + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 2 (VRC01LS + 10-1074 Only) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 | —700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results—700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination —60 mg/kg NCT05291520 · Phase 1 · monotherapy —20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Serious AEs | —Group PK-B: ART + 10-1074 NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 show 3 more results0%PK Step (ART + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 0%Step 1 (ART + VRC01LS + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 4%Step 2 (VRC01LS + 10-1074 Only) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 | 0%700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results0%700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 18.8%700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 25%700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 12.5%70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 12.5%40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination 0%60 mg/kg NCT05291520 · Phase 1 · monotherapy 0%20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Most frequent reported AEs | show 2 more resultsneutrophil count decreased 35.7% haemoglobin decreased 28.6% cough 25% NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 cough 44% upper respiratory tract infection 32% haemoglobin decreased 28% NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 | 700 mg IVa influenza 12.5% rhinitis 12.5% aspartate aminotransferase increased 6.3% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results700 mg SC headache 18.8% blood creatine phosphokinase increased 12.5% neutropenia 12.5% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 700 mg IV upper respiratory tract infection 18.8% anaemia 12.5% anogenital warts 6.3% NCT04871113 · Phase 2 · combination · HIV · phase 2 700 mg SC neutropenia 12.5% pharyngitis 12.5% tonsillitis 12.5% NCT04871113 · Phase 2 · combination · HIV · phase 2 280 mg IV abdominal pain 16.7% asthenia 16.7% bronchitis 16.7% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 280 mg IV depression 16.7% hypertension 16.7% influenza like illness 16.7% NCT04871113 · Phase 2 · combination · HIV · phase 2 70 mg IV covid-19 12.5% alanine aminotransferase increased 6.3% anal abscess 6.3% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 70 mg IV upper respiratory tract infection 12.5% vomiting 12.5% abdominal pain 6.3% NCT04871113 · Phase 2 · combination · HIV · phase 2 40 mg/kg IV abdominal pain 12.5% blood creatine phosphokinase increased 12.5% covid-19 12.5% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 40 mg/kg IV covid-19 25% proctitis gonococcal 25% syphilis 25% NCT04871113 · Phase 2 · combination · HIV · phase 2 3000 mg + rHuPH20 injection site erythema 100% injection site bruising 25% injection site pain 25% NCT05291520 · Phase 1 · combination 60 mg/kg medical device site dermatitis 12.5% muscle tightness 12.5% covid-19 0% NCT05291520 · Phase 1 · monotherapy 20 mg/kg + rHuPH20 injection site erythema 87.5% upper respiratory tract infection 25% headache 12.5% NCT05291520 · Phase 1 · combination |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lotivibart
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · Lotivibart's landscape